Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1.
about
A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma.Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma.Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As2O3) and all-trans retinoic acid (ATRA).
P2860
Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1.
@en
Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1.
@nl
type
label
Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1.
@en
Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1.
@nl
prefLabel
Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1.
@en
Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1.
@nl
P2860
P1433
P1476
Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1.
@en
P2093
Rico K H Lo
Yok-Lam Kwong
P2860
P304
P356
10.1007/S00277-013-1866-2
P577
2013-08-15T00:00:00Z